Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007
June 19 2007 - 6:17PM
PR Newswire (US)
SAN DIEGO, June 19 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced that data
featuring its approved diabetes drugs, BYETTA(R) (exenatide)
injection and SYMLIN(R) (pramlintide acetate) injection, and its
pipeline candidates will be presented at the American Diabetes
Association's (ADA) 67th Annual Scientific Sessions being held in
Chicago, IL from June 22 to 26. The company will also host an
investor presentation during the meeting that will be available by
webcast. ADA is one of the largest scientific meetings for
endocrinologists and other health care professionals involved in
diabetes research and delivery of diabetes care. Data from several
studies will be highlighted in oral presentations and poster
sessions that will provide insight into Amylin's approved diabetes
drugs, BYETTA and SYMLIN and the company's research and development
programs. Additional information will also be presented during two
symposia focused on the multihormonal approach to treatment of
diabetes and obesity, and the role of incretin-based therapies in
type 2 diabetes. "Our activities at this year's ADA will reinforce
the important therapeutic benefits of BYETTA and SYMLIN and focus
on novel peptide hormones and their potential to treat obesity,"
said Daniel M. Bradbury, President and Chief Executive Officer of
Amylin Pharmaceuticals, Inc. "We are dedicated to bringing
innovative medicines with life-changing therapeutic potential to
patients. Our broad clinical program is designed to continue
transforming the care of diabetes and obesity." KEY AMYLIN
ABSTRACTS BEING PRESENTED AT ADA: 1. Oral: "Less Hypoglycemia with
Exenatide Versus Insulin Glargine, Despite Similar HbA1c
Improvement in Patients with T2DM Adjunctively Treated with
Metformin" will be presented by Michael E. Trautmann, M.D. on
Sunday, June 24 at 3:45 PM CT (4:45 PM ET). 2. Oral: "Exenatide
Maintained Glycemic Control with Associated Weight Reduction Over
Three Years in Patients with Type 2 Diabetes" will be presented by
John B. Buse, M.D. on Monday, June 25 at 3:15 PM CT (4:15 PM ET).
3. Poster: "Improvements in Cardiovascular Risk Factors Accompanied
Improved Glycemic Control and Weight Reduction in Patients with
Type 2 Diabetes Treated with Exenatide for 3.5 y" will be presented
by David Kendall, M.D. during a poster session on Sunday, June 24
at 12:00 PM CT (1:00 PM ET). 4. Poster: "Pramlintide Improved
Glycemic Control without Increased Risk of Hypoglycemia in Patients
with Type 2 Diabetes Using Basal Insulin" will be presented by
Karen Lutz, Ph.D. during a poster session on Sunday, June 24 at
12:00 PM CT (1:00 PM ET). 5. Oral: "Responsiveness to Leptin
Restored by Amylin in Diet Induced Obese (DIO) Rats: Magnitude and
Mechanisms of Synergy" will be presented by Jonathan Roth, Ph.D. on
Monday, June 25 at 3:45 PM CT (4:45 PM ET). 6. Oral: "Sustained
Weight Loss Following 1-y Pramlintide Treatment as an Adjunct to
Lifestyle Intervention in Obesity" will be presented by Steven
Smith, M.D. on Monday, June 25 at 5:30 PM CT (6:30 PM ET). A full
list of all Amylin abstracts being presented at ADA is available
at: http://scientificsessions.diabetes.org/. FEATURED SYMPOSIA 1.
"The Diabetes-Obesity Continuum: The Growing Body of Evidence for a
Multihormonal Approach to Treatment." This medical education
symposium will help healthcare providers understand the potential
of multihormonal treatment approaches for diabetes and obesity. The
event will be chaired by Carol Hatch Wysham, M.D. on Sunday, June
24 at 5:30 AM CT (6:30 AM ET). This symposium is supported by an
unrestricted educational grant from Amylin Pharmaceuticals. 2. "The
Role of Incretin-Based Therapies: Reconstructing Treatment
Approaches in Type 2 Diabetes." This medical education symposium
will help healthcare providers understand the role of
incretin-based therapies in relation to type 2 diabetes. The event
will be chaired by Bernard Zinman, M.D. on Monday, June 25 at 5:30
AM CT (6:30 AM ET). This symposium is supported by an unrestricted
educational grant from Amylin Pharmaceuticals and Eli Lilly and Co.
Amylin will also conduct a webcast for investors to review the
information presented at ADA on Sunday, June 24 at 7:30 PM CT (8:30
PM ET). The live presentation will be webcast, and a recording will
be made available following the event. The webcast and recording
will be accessible through Amylin's corporate Web site, located at
http://www.amylin.com/. To access the live webcast, please log on
to Amylin's site approximately 15 minutes prior to the presentation
to register and download any necessary audio software. More
information about ADA can be found at
http://scientificsessions.diabetes.org/. About Amylin
Pharmaceuticals Amylin Pharmaceuticals is a biopharmaceutical
company committed to improving lives through the discovery,
development and commercialization of innovative medicines. Amylin
has developed and gained approval for two first-in-class medicines
for diabetes, SYMLIN(R) (pramlintide acetate) injection and
BYETTA(R) (exenatide) injection. Amylin's research and development
activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin
is located in San Diego, California with over 1,700 employees
nationwide. For more information about Amylin visit
http://www.amylin.com/. This press release contains forward-looking
statements about Amylin, which involve risks and uncertainties.
Amylin's actual results could differ materially from those
discussed herein due to a number of risks and uncertainties,
including risks that BYETTA or SYMLIN, and the revenues Amylin
generates from these products, may be affected by competition,
unexpected new data, technical issues, or manufacturing and supply
issues; risks that the results of pre-clinical studies or clinical
trials may not be predictive of future results; risks that our
clinical trials will not start or be completed when planned; risks
that the FDA may not approve Amylin's regulatory submissions; and
risks inherent in the drug development and commercialization
process. Commercial and government reimbursement and pricing
decisions and the pace of market acceptance may also affect the
potential for BYETTA or SYMLIN. These and additional risks and
uncertainties are described more fully in Amylin's recently filed
Form 10-Q. Amylin disclaims any obligation to update these
forward-looking statements. DATASOURCE: Amylin Pharmaceuticals,
Inc. CONTACT: Alice Bahner Izzo of Amylin Pharmaceuticals, Inc.,
+1-858-642-7272, cell, +1-858-232-9072, ; or Rachel Martin of
Edelman, +1-323-202-1031, cell, +1-323-373-5556, , for Amylin
Pharmaceuticals, Inc. Web site: http://www.amylin.com/
http://scientificsessions.diabetes.org/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024